|
Deferred Research And Development Arrangement (Details) (USD $)
|
12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
Rexgene [Member]
|
Dec. 31, 2012
Rexgene [Member]
|
Dec. 31, 2003
Rexgene [Member]
|
Dec. 31, 2013
Teva Pharmaceutical Industries, Ltd. [Member]
|
Dec. 31, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
Nov. 27, 2012
Teva Pharmaceutical Industries, Ltd. [Member]
|
|
| Research and development arrangement, one-time fee | $ 1,500,000 | |||||||
| Reduction of research and development expenses | 75,000 | 75,000 | 717,370 | 50,000 | ||||
| Deferred Research and Development Arrangement | 833,630 | 1,626,000 | 675,000 | 750,000 | 158,630 | 876,000 | ||
| Royalties paid, percentage of net sales | 3.00% | |||||||
| Restricted Cash and Cash Equivalents, Noncurrent | $ 196,130 | $ 1,091,801 | $ 926,000 | |||||